 Home > Active Ingredient News > Drugs Articles > Simcere Pharmaceuticals and Kazia Therapeutics announce the signing of an exclusive license agreement for the anti-tumor drug Paxalisib in Greater China

Simcere Pharmaceuticals and Kazia Therapeutics announce the signing of an exclusive license agreement for the anti-tumor drug Paxalisib in Greater China

 Last Update: 2021-04-19
 Source: Internet
 Author: User

Tags

blood work hematocrit

hctz drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

us" style='margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.

Nanjing, China, March 29, 2021-Simcere Pharmaceutical Group Co.
, Ltd.
(HKSE: 2096, hereinafter referred to as "Sincere Pharmaceutical") announced that its subsidiary has signed an exclusive license agreement with the Australian oncology drug development company Kazia Therapeutics.
Introduce Paxalisib's rights to develop and commercialize all indications in Greater China (Mainland China, Hong Kong, Macau and Taiwan).

5);box-shadow:#000000 0px 0px 0px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;font-size:14px;line-height:1.
75;letter-spacing:1px;color:#3E3E3E;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;font-size:14px;line-height:1.
75;letter-spacing:1px;color:#3E3E3E;">

us" style='margin:-3px 0px 25px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;letter-spacing:0.
544px;white-space:normal;background-color:#FFFFFF;text-align:right;justify-content:flex-end;font-size:0px;overflow-wrap:break-word ;'>688px;background-color:#00B140;border-width:0px;">688px;background-color:#00B140;border-width:0px;">us" style='margin:0px;padding:0px 8px;max-width:100%;box-sizing:border-box;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
8;letter-spacing:1px;font-size:14px;color:#3E3E3E;overflow-wrap:break-word ;'>

Paxalisib is a permeable brain PI3K / mTOR pathway inhibitors , ongoing global Ⅱ / Ⅲ stage of GBM AGILE glioblastoma platform for clinical trials.

Paxalisib is a permeable brain PI3K / mTOR pathway inhibitors , ongoing global Ⅱ / Ⅲ stage of GBM AGILE glioblastoma platform for clinical trials.
Brain-permeable PI3K/mTOR pathway inhibitor Brain-permeable PI3K/mTOR pathway inhibitor Stage Ⅱ/Ⅲ GBM AGILE glioblastomaus" style='margin:10px 0px 25px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;justify-content:center;overflow-wrap:break-word ;'>094px;vertical-align:top;height:auto;border-style:solid;border-width:1px;border-color:#00B140;overflow-wrap:break-word ;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:0px 0px 5px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:center;font-size:0px;">
us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:center;font-size:0px;">
us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;transform:translate3d(1px, 0px, 0px);">8;letter-spacing:1px;">

Pre-clinical studies have shown that Paxalisib has efficient blood-brain barrier penetration .

The interim data of the phase II clinical study announced at the annual meeting of the American Society of Neuro-Oncology (SNO) in November 2020 showed that Paxalisib was used in MGMT non-methylated new-haired glioblastoma (GBM) patients with a median survival The median progression-free survival (mOS) and median progression-free survival (mPFS) were 17.
5 months and 8.

us" style="margin:0px 0px 5px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:center;font-size:0px;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;transform:translate3d(1px, 0px, 0px);">8;letter-spacing:1px;">

Pre-clinical studies have shown that Paxalisib has efficient blood-brain barrier penetration .

8;letter-spacing:1px;">

Pre-clinical studies have shown that Paxalisib has efficient blood-brain barrier penetration .
The interim data of the phase II clinical study announced at the annual meeting of the American Society of Neuro-Oncology (SNO) in November 2020 showed that Paxalisib was used in MGMT non-methylated new-haired glioblastoma (GBM) patients with a median survival The median progression-free survival (mOS) and median progression-free survival (mPFS) were 17.
5 months and 8.
4 months, respectively , which were significantly improved compared with the existing standard treatment literature data of 12.
7 months and 5.
3 months.

Efficient blood-brain barrier penetration Efficient blood-brain barrier penetration 17.
5 17.
5 17.
5 8.
4 8.
4 8.
4 12.
7 12.
7 12.
7 5.
3 5.
3 5.
3us" style="margin:0px 0px 5px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:center;font-size:0px;">
us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:0px;">
us" style="margin:0px 0px 5px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:center;font-size:0px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:0px;">544px;white-space:normal;background-color:#FFFFFF;text-align:center;overflow-wrap:break-word ;'>us" style='margin:0px 0px 10px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>8;letter-spacing:1px;font-size:14px;color:#3E3E3E;">

According to the agreement, Simcere will be responsible for the development, registration and commercialization of Paxalisib in the Greater China region.

Kazia Therapeutics will receive down payment, milestone payment and sales share in China.

Dr.

Tang Renhong, Executive Director and Senior Vice President of Simcere Pharmaceuticals, said:

8;letter-spacing:1px;font-size:14px;color:#3E3E3E;">

According to the agreement, Simcere will be responsible for the development, registration and commercialization of Paxalisib in the Greater China region.

Kazia Therapeutics will receive down payment, milestone payment and sales share in China.

Dr.

Tang Renhong, Executive Director and Senior Vice President of Simcere Pharmaceuticals, said:

According to the agreement, Simcere will be responsible for the development, registration and commercialization of Paxalisib in the Greater China region.

Kazia Therapeutics will receive down payment, milestone payment and sales share in China.

Dr.
Tang Renhong, Executive Director and Senior Vice President of Simcere Pharmaceuticals, said:

Dr.
Tang Renhong, Executive Director and Senior Vice President of Simcere Pharmaceuticals said: Dr.
Tang Renhong, Executive Director and Senior Vice President of Simcere Pharmaceuticals, said:us" style='margin:0px 0px 25px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">2em;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

Glioblastoma is one of the most malignant tumors, and clinical treatment options are very limited.
We are very happy to see Paxalisib make a breakthrough in this challenging field.
Chinese patients with brain tumors urgently need new treatments, and we look forward to working with Kazia to bring new treatments to more patients.

11em 0px 0px -0.
1em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;font-size:75px;color:#006341;">"us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">2em;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

11em 0px 0px -0.
1em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;font-size:75px;color:#006341;">"2em;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

11em 0px 0px -0.
1em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;font-size:75px;color:#006341;">"5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">"6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

8;letter-spacing:1px;">

11em 0px 0px -0.
1em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;font-size:75px;color:#006341;">"11em 0px 0px -0.
1em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;font-size:75px;color:#006341;">"us" style='margin:0px 0px 10px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>8;letter-spacing:1px;color:#1D1D1D;">

Dr.
James Garner, CEO of Kazia said:

8;letter-spacing:1px;color:#1D1D1D;">

Dr.
James Garner, CEO of Kazia said:

Kazia CEO Dr.
James Garner said: Kazia CEO Dr.
James Garner said:us" style='margin:0px 0px 25px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">2em;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

We are very happy to work with Simcere to ensure the success of Paxalisib in this important market in China.
Simcere has first-class clinical development, drug registration, and commercialization experience and teams in China.
We look forward to working closely with Simcere, and Paxalisib will benefit Chinese patients as soon as possible.
"

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">2em;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

2em;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;vertical-align:top;line-height:1em;height:1em;">" 6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">"6em 0px 0px -0.
6em;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;width:4em;border-bottom:1px solid #006341;display:inline-block;vertical-align:middle;">5em 0px 0px;padding:10px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

us" style="margin:10px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1px;">

8;letter-spacing:1px;">

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.